PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
October 15, 2025International Journal of Scientific Research

Predictive Impact of Pan-Immune Inflammation Value on Radiological Response in Metastatic Breast Cancer Patients on Palbociclib

View Full Paper
Ask AI
Bookmark
Share

Authors

KLK. N. LokeshGSGuruprasad C. ShenoyGGG.V. Giri

Discussion

Loading...

Member takes

Overview

Retrospective observational study finds pan-immune inflammation value predicts radiological response in HR+/HER2− metastatic breast cancer patients undergoing palbociclib therapy.

Key Points

  • Higher pan-immune inflammation value correlates with worse radiological outcomes in metastatic breast cancer patients.
  • At 6 months, disease control was found in 54.2% low PIV patients compared to only 26.3% in high PIV patients.
  • Mean PIV values significantly differed across response categories, with lower values indicating better responses.
  • Baseline PIV serves as an inexpensive, reproducible biomarker for guiding personalized treatment in breast cancer.

Cite This Study

Lokesh et al. (2025) studied this question.

synapsesocial.com/papers/68f02c7d616531447b5f9362https://doi.org/10.36106/ijsr/1908569
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pan-Immune-Inflammation Value: A Novel Marker for Chemotherapy Response in Locally Advanced Breast Cancer2025 · 1 citations
  2. 2Prognostic value of pan-immune-inflammation in breast cancer patients with lymph node metastasis and neoadjuvant therapy2025 · 1 citations
  3. 3The Pan-immune-inflammation Value Predicts the Survival of Patients with Breast Cancer2024
  4. 4Pan-immune-inflammation value: racial variations and differences in prognostic accuracy across breast cancer subtypes at a single institution2026
  5. 5Prospective evaluation of the pan-immune-inflammation value (PIV) as an independent prognostic biomarker in EGFR-mutated advanced non-small cell lung cancer.2026